Childhood-onset Takayasu arteritis: clinical presentation, challenges and disease course.

IF 2.3 3区 医学 Q1 PEDIATRICS
L Peremans, M Twilt, A Fifi-Mah, N Johnson, D Mosher, A Wade, L Hamiwka
{"title":"Childhood-onset Takayasu arteritis: clinical presentation, challenges and disease course.","authors":"L Peremans, M Twilt, A Fifi-Mah, N Johnson, D Mosher, A Wade, L Hamiwka","doi":"10.1186/s12969-025-01147-7","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Takayasu arteritis (TAK) is a rare granulomatous inflammatory vasculitis primarily affecting the aorta and its major branches. Data on childhood-onset TAK (c-TAK) remain scarce. This study retrospectively evaluates the clinical presentation, disease flares, treatment, and outcomes of c-TAK in a tertiary Canadian center.</p><p><strong>Methods: </strong>We identified all children under 18 years of age at disease onset with a clinical diagnosis of TAK seen at Alberta Children's Hospital, Calgary, Canada, between 2000 and 2024. Patients meeting the EULAR/PRINTO/Pres classification criteria for c-TAK were included. Baseline demographic data, clinical presentation, laboratory findings, imaging results, disease flares, and treatment were documented. Additionally, we highlight two challenging cases due to their particularly complex disease trajectories.</p><p><strong>Results: </strong>Six children (4 female) with a median age at diagnosis of 14.5 years (range: 4-17) met the classification criteria for c-TAK. Clinical presentation was variable, with the most common symptoms being fatigue (n = 4), weight loss (n = 3), and hypertension (n = 3). The most frequently affected arteries were the abdominal aorta and carotid arteries (n = 5) followed by ascending aorta (n = 4). All patients received corticosteroids for induction treatment. Additional immunosuppressive therapies included methotrexate (n = 5), infliximab (n = 2), tocilizumab (n = 2), IVIG (n = 2), etanercept (n = 1), adalimumab (n = 1), and cyclophosphamide (n = 1).</p><p><strong>Conclusions: </strong>TAK is a rare, potentially life-threatening large-vessel vasculitis. Early recognition is crucial for timely diagnosis and aggressive treatment initiation. Children with TAK often experience a complex disease course requiring multiple treatment adjustments and surgical or endovascular interventions. Large, multinational collaborations are essential for advancing our knowledge and improving patient outcomes.</p>","PeriodicalId":54630,"journal":{"name":"Pediatric Rheumatology","volume":"23 1","pages":"94"},"PeriodicalIF":2.3000,"publicationDate":"2025-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12482566/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pediatric Rheumatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s12969-025-01147-7","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PEDIATRICS","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Takayasu arteritis (TAK) is a rare granulomatous inflammatory vasculitis primarily affecting the aorta and its major branches. Data on childhood-onset TAK (c-TAK) remain scarce. This study retrospectively evaluates the clinical presentation, disease flares, treatment, and outcomes of c-TAK in a tertiary Canadian center.

Methods: We identified all children under 18 years of age at disease onset with a clinical diagnosis of TAK seen at Alberta Children's Hospital, Calgary, Canada, between 2000 and 2024. Patients meeting the EULAR/PRINTO/Pres classification criteria for c-TAK were included. Baseline demographic data, clinical presentation, laboratory findings, imaging results, disease flares, and treatment were documented. Additionally, we highlight two challenging cases due to their particularly complex disease trajectories.

Results: Six children (4 female) with a median age at diagnosis of 14.5 years (range: 4-17) met the classification criteria for c-TAK. Clinical presentation was variable, with the most common symptoms being fatigue (n = 4), weight loss (n = 3), and hypertension (n = 3). The most frequently affected arteries were the abdominal aorta and carotid arteries (n = 5) followed by ascending aorta (n = 4). All patients received corticosteroids for induction treatment. Additional immunosuppressive therapies included methotrexate (n = 5), infliximab (n = 2), tocilizumab (n = 2), IVIG (n = 2), etanercept (n = 1), adalimumab (n = 1), and cyclophosphamide (n = 1).

Conclusions: TAK is a rare, potentially life-threatening large-vessel vasculitis. Early recognition is crucial for timely diagnosis and aggressive treatment initiation. Children with TAK often experience a complex disease course requiring multiple treatment adjustments and surgical or endovascular interventions. Large, multinational collaborations are essential for advancing our knowledge and improving patient outcomes.

儿童期高须动脉炎:临床表现、挑战和病程。
背景:高松动脉炎是一种罕见的肉芽肿性炎症性血管炎,主要影响主动脉及其主要分支。关于儿童期发病TAK (c-TAK)的数据仍然很少。本研究回顾性评价了加拿大某三级中心c-TAK的临床表现、疾病发作、治疗和预后。方法:我们选取了2000年至2024年间在加拿大卡尔加里阿尔伯塔儿童医院就诊的所有18岁以下发病且临床诊断为TAK的儿童。纳入符合EULAR/PRINTO/Pres c-TAK分类标准的患者。记录了基线人口统计数据、临床表现、实验室结果、影像学结果、疾病发作和治疗情况。此外,由于其特别复杂的疾病轨迹,我们强调了两个具有挑战性的病例。结果:6例患儿(女4例)符合c-TAK的分型标准,诊断时中位年龄14.5岁(范围4-17岁)。临床表现不同,最常见的症状是疲劳(n = 4)、体重减轻(n = 3)和高血压(n = 3)。最常见的动脉是腹主动脉和颈动脉(n = 5),其次是升主动脉(n = 4)。所有患者均接受皮质类固醇诱导治疗。其他免疫抑制疗法包括甲氨蝶呤(n = 5)、英夫利昔单抗(n = 2)、托珠单抗(n = 2)、IVIG (n = 2)、依那西普(n = 1)、阿达木单抗(n = 1)和环磷酰胺(n = 1)。结论:TAK是一种罕见的、可能危及生命的大血管炎。早期识别对于及时诊断和积极治疗至关重要。患有TAK的儿童通常经历复杂的病程,需要多次治疗调整和手术或血管内干预。大型跨国合作对于提高我们的知识和改善患者的治疗效果至关重要。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Pediatric Rheumatology
Pediatric Rheumatology PEDIATRICS-RHEUMATOLOGY
CiteScore
4.10
自引率
8.00%
发文量
95
审稿时长
>12 weeks
期刊介绍: Pediatric Rheumatology is an open access, peer-reviewed, online journal encompassing all aspects of clinical and basic research related to pediatric rheumatology and allied subjects. The journal’s scope of diseases and syndromes include musculoskeletal pain syndromes, rheumatic fever and post-streptococcal syndromes, juvenile idiopathic arthritis, systemic lupus erythematosus, juvenile dermatomyositis, local and systemic scleroderma, Kawasaki disease, Henoch-Schonlein purpura and other vasculitides, sarcoidosis, inherited musculoskeletal syndromes, autoinflammatory syndromes, and others.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信